Top of this page
Skip navigation, go straight to the content

Our Company

Disease Areas

Our Science

UCB Worldwide

 Search

Our Products

Newsroom

Patients

Investors

FOLLOW US ON
© 2007 – 2019 UCB S.A., Belgium. All rights reserved.
Newsroom • Press Releases

Search Press releases


Transparency notification BlackRock, Inc.19 Mar 2019

Transparency notification BlackRock, Inc.

Read more
Transparency notification UCB SA/NV13 Mar 2019

Transparency notification UCB SA/NV

Read more
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)11 Mar 2019

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study …

Read more
Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study 28 Feb 2019

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete …

Read more
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio28 Feb 2019

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

Read more
UCB Full Year Report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipeline27 Feb 2019

UCB Full Year Report 2018: 2018 marks the fifth …

Read more


Stay up-to-date on the latest news and information from UCB